Pfizer recently broke ground on its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company's presence in the state, Pfizer will invest more than $200 million in development of the 175,000-square-foot facility, which will enable the production of complex biologics and vaccines.
The new five-story building is expected to be operational by January 2019. Approximately 75 new employees will be hired to support clinical manufacturing.
In addition to the Andover campus, Massachusetts is home to Pfizer's research and development hub in Cambridge. The company has approximately 2,000 employees based in Massachusetts.
Pfizer's Andover campus currently includes seven buildings, which house laboratories, clinical and commercial manufacturing suites, and support areas. It also includes a multiproduct manufacturing facility that allows clinical and commercial products to be manufactured simultaneously.
The new clinical manufacturing facility is designed with five independent manufacturing suites to support Pfizer's biologics research effort. The facility will employ flexible design to fully enable next-generation manufacturing strategies and leverage single-use bioreactors and disposable process technologies.
"The expansion of Pfizer's presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve," said John Ludwig, Pfizer's senior vice president of biotherapeutics pharmaceutical sciences. "Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years."
For more information, visit www.pfizer.com.
